FDA Approves Innovative Daily Psoriasis Pill, Securing a $50 Million Milestone for Protagonist
Newark, Wednesday, 18 March 2026.
The FDA’s March 18, 2026, approval of ICOTYDE, a novel once-daily psoriasis pill, triggers an immediate $50 million payout for Protagonist Therapeutics, alongside substantial future royalty potential.
A Breakthrough in Psoriasis Treatment
On March 18, 2026, Protagonist Therapeutics, Inc. and Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved ICOTYDE™ (icotrokinra) [1][3]. The regulatory agency officially authorized the drug on March 17, 2026. This novel medication is indicated for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients who are 12 years of age and older, weighing at least 40 kilograms, and who are candidates for systemic therapy or phototherapy [2][3]. ICOTYDE distinguishes itself as the first and only targeted oral peptide designed to precisely block the Interleukin-23 receptor (IL-23R) [1][3].